Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Foghorn Therapeutics Q3 2026 Results: Turns Profitable, Net Income $58.1M

Foghorn Therapeutics reported a significant increase in collaboration revenue to $83.5 million for the third quarter of 2026, resulting in a net income of $58.2 million compared to a net loss in the prior year. The company also improved its stockholders' deficit from $108.5 million at the end of 2025 to $14.1 million as of September 30, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue83.58.2
Net income58.1-15.8
EPS (diluted, $ a share)$0.80$-0.25

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+924.7%
Operating margin67.8%
Source

10-Q filed with the SEC, NASDAQ: FHTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Foghorn Therapeutics Inc.: key numbers

Share price
$1.83Close, Nov 17
Market cap
$110M
Shares outstanding
59.96MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Foghorn Therapeutics Inc.

All →
7:07 AM ET 8-K
Financial Results

Foghorn Therapeutics Financial Results

Foghorn Therapeutics reported Q3 2026 financial results, highlighted by a significant increase in collaboration revenue to $83.5 million due to a cumulative catch-up adjustment. The company reported a net income of $44.5 million for the quarter and maintains a cash runway into the second half of 2029 to support its oncology and immunology pipelines.

“Our focus is on advancing our wholly owned portfolio, including our novel, oral I&I program in IBD, with potential for first-in-human trials by the end of 2027, and our Selective EP300 degrader which has an IND targeted for next year. We are also advancing a novel induced-proximity approach with the potential to deliver antibody-like efficacy against high-value secreted and transmembrane proteins through small molecules. With cash runway into the second half of 2029, we are well positioned to deliver on this strategy.”

Adrian Gottschalk, President and Chief Executive Officer
7:01 AM ET 8-K
Other 8-K Filing

Foghorn Therapeutics Other 8-K Filing

Foghorn Therapeutics and Eli Lilly have decided to discontinue the clinical development of FHD-909 and their SMARCA2 degrader collaboration following a review of Phase 1 data. Consequently, Foghorn is implementing a strategic reprioritization and a 40% workforce reduction to extend its cash runway into the second half of 2029, incurring approximately $2.3 million in severance-related charges.

Counterparty
Eli Lilly and Company

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.